{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:50:22Z","timestamp":1782276622445,"version":"3.54.5"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HER2-positive breast cancer represents approximately 15-20% of all breast cancers and is characterized by aggressive biological behavior. Neoadjuvant chemotherapy (NAC) has become standard treatment, with pathological complete response (pCR) serving as a crucial prognostic indicator. This study aimed to develop and validate a nomogram integrating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) features and clinicopathological parameters for predicting pCR in HER2-positive breast cancer patients receiving NAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 183 HER2-positive breast cancer patients who received NAC followed by surgery between January 2015 and December 2024. After excluding 17 patients with incomplete data, 166 patients were randomly divided into training (n=111) and validation (n=55) cohorts. DCE-MRI imaging features including tumor size, lymph node status, apparent diffusion coefficient (ADC) values, and tumor location parameters were extracted. Clinicopathological variables including age, BMI, hormone receptor status, Ki-67 index, clinical staging, and treatment regimen were analyzed. Molecular characterization and multi-omics feature analysis were performed to identify independent predictors of pCR. A nomogram was constructed and validated using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall pCR rate was 44.6% (74\/166 evaluable patients). Molecular subtype analysis revealed significantly higher pCR rates in HR-\/HER2+ patients (52.2%) versus HR+\/HER2+ patients (38.5%, P\u00a0=\u00a00.048). Gene set enrichment analysis identified HER2 signaling and cell proliferation pathways as the most significantly enriched pathways in pCR responders. Multi-omics feature integration identified ADCmin value, Ki-67 index, tumor size, clinical N stage, and HR status as independent predictors. The nomogram demonstrated excellent discrimination with AUC of 0.823 (95%CI: 0.754-0.892) in the training cohort and 0.795 (95%CI: 0.691-0.899) in the validation cohort. Calibration plots showed good agreement (Hosmer-Lemeshow P\u00a0=\u00a00.412). DCA confirmed clinical utility across threshold probabilities of 0.15-0.75.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We successfully developed and validated a nomogram integrating DCE-MRI features and clinicopathological parameters for predicting pCR in HER2-positive breast cancer. This practical tool may facilitate individualized treatment decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1827442","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:44:29Z","timestamp":1782276269000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A nomogram integrating DCE-MRI imaging features and clinicopathological parameters for predicting pathological complete response in HER2-positive breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Jianlong","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Breast Oncology, Center for Cancer Prevention and Treatment, Meizhou People\u2019s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences","place":["Meizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Center for Cancer Prevention and Treatment, Meizhou People\u2019s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences","place":["Meizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingna","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Center for Cancer Prevention and Treatment, Meizhou People\u2019s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences","place":["Meizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Center for Cancer Prevention and Treatment, Meizhou People\u2019s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences","place":["Meizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Center for Cancer Prevention and Treatment, Meizhou People\u2019s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences","place":["Meizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyou","family":"Zhong","sequence":"additional","affiliation":[{"name":"Radiotherapy Center, Center for Cancer Prevention and Treatment, Meizhou People\u2019s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences","place":["Meizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxia","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Center for Cancer Prevention and Treatment, Meizhou People\u2019s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences","place":["Meizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Center for Cancer Prevention and Treatment, Meizhou People\u2019s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences","place":["Meizhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\/CAP guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA)","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/s1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with HER2-positive breast cancer (NeoSphere)","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2108-2","article-title":"Recommendations from an international consensus conference on neoadjuvant systemic therapy in primary breast cancer","volume":"19","author":"Kaufmann","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx308","article-title":"De-escalating and escalating treatments for early-stage breast cancer: St. Gallen 2017","volume":"28","author":"Curigliano","year":"2017","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant chemotherapy regimens (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus T-DM1 plus pertuzumab (KRISTINE)","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000002313","article-title":"Clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy","volume":"267","author":"Kuerer","year":"2018","journal-title":"Ann Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju152","article-title":"Molecular features and survival outcomes of intrinsic subtypes within HER2-positive breast cancer","volume":"106","author":"Prat","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs528","article-title":"Meta-analysis of MRI in detecting residual breast cancer after neoadjuvant therapy","volume":"105","author":"Marinovich","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-015-3807-z","article-title":"Breast MRI: EUSOBI recommendations for women's information","volume":"25","author":"Mann","year":"2015","journal-title":"Eur Radiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mri.2005.11.005","article-title":"Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer","volume":"24","author":"Pickles","year":"2006","journal-title":"Magn Reson Imaging"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-9842-y","article-title":"DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy","volume":"29","author":"Li","year":"2012","journal-title":"Med Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.12110748","article-title":"Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--ACRIN 6657\/I-SPY TRIAL","volume":"263","author":"Hylton","year":"2012","journal-title":"Radiology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)71116-7","article-title":"Nomograms in oncology: more than meets the eye","volume":"16","author":"Balachandran","year":"2015","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.12.9791","article-title":"How to build and interpret a nomogram for cancer prognosis","volume":"26","author":"Iasonos","year":"2008","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.12126","article-title":"Discrimination and calibration of clinical prediction models","volume":"318","author":"Alba","year":"2017","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.01.2898","article-title":"Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer","volume":"23","author":"Rouzier","year":"2005","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018172868","article-title":"Dynamic contrast-enhanced breast MRI for evaluating residual tumor size after neoadjuvant chemotherapy","volume":"289","author":"Kim","year":"2018","journal-title":"Radiology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/0272989x06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-013-2850-x","article-title":"Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in breast cancer","volume":"23","author":"Richard","year":"2013","journal-title":"Eur Radiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1148\/radiol.10092021","article-title":"Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in breast cancer","volume":"257","author":"Park","year":"2010","journal-title":"Radiology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018180273","article-title":"Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: ACRIN 6698","volume":"289","author":"Partridge","year":"2018","journal-title":"Radiology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1016\/j.breast.2017.06.038","article-title":"Neoadjuvant therapy for triple negative and HER2-positive early breast cancer","volume":"34","author":"Harbeck","year":"2017","journal-title":"Breast"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.63.1010","article-title":"Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"732047","DOI":"10.1007\/s12254-025-01079-8","article-title":"Neoadjuvant chemotherapy and targeted therapy in breast cancer","volume":"2013","author":"Gampenrieder","year":"2013","journal-title":"J Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1827442\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:44:37Z","timestamp":1782276277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1827442\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1827442"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1827442","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1827442"}}